secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018800
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q1 net loss narrows to $43M; DAYBUE approved and launched for Rett syndrome
--------------------------------------------------------------------------------

- NUPLAZID net sales $118.5M, up 3% YoY; demand grew ~2%.
- Net loss $43.0M ($0.27/share) vs $113.1M ($0.70/share) in Q1 2022.
- DAYBUE (trofinetide) FDA-approved March 10; launched April 17 for Rett syndrome.
- Phase 3 pimavanserin trial for negative schizophrenia symptoms nearing enrollment; results expected early 2024.
- 2023 guidance reaffirmed: NUPLAZID sales $520-$550M, R&D $235-$255M, SG&A $360-$380M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/0000950170-23-018800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/acad-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer